(Q34578099)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

main subject

phase II clinical trial

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Palma Dileo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Jeffrey A Morgan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David Zahrieh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Jeanine M Salesi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David C Harmon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

M Travis Quigley

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Kathleen Polson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

George D Demetri

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Suzanne George

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

English

0 references

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

1863-1869

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17385194%20AND%20SRC:MED&resulttype=core&format=json

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Confidence limits for probability of response in multistage phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22609

7 January 2021